[1441]
Acute myeloid and T-cell acute lymphoblastic leukaemia with ...
[4,2 KB]
From [www.charite.de] Last viewed: 13.07.2004
leukaemia
Acute myeloid and T-cell acute lymphoblastic leukaemia with aberrant antigen expression exhibit similar TCRdelta gene rearrangements. Schmidt-CA; Przybylski-G; Tietze-A; Oettle-H; Siegert-W; Ludwig-WD Virchow Klinikum, Abt. Hamatologie und Onkologie, Humboldt Universitat Berlin, Germany. Br-J-Haematol. 1996 Mar; 92(4): 929-36
A prospective study of human herpesvirus type 6 detected by polymerase chain reaction after liver transplantation. Schmidt-CA; Wilbron-F; Weiss-K; Brinkmann-V; Oettle-H; Lohmann-R; Langrehr-JM; Neuhaus-P; Siegert-W Abteilung fur Innere Medizin und Poliklinik mit Schwerpunkt Hamatologie und Onkologie, Universitatsklinikum Rudolf Virchow, Freie Universitat, Berlin, Germany. Transplantation. 1996 Feb 27; 61(4): 662-4
Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts ...
[1442]
ADULT LEUKAEMIA WORKING PARTY
[66,0 KB]
From [www.aml15.bham.ac.uk] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1443]
MED-B FORM CHRONIC MYELOID LEUKAEMIA
[94,8 KB]
From [www.ebmt.org] Last viewed: 13.07.2004
EBMT
European Group for Blood and Marrow Transplantation
MED-B FORM
CHRONIC MYELOID
LEUKAEMIA
For registration of
ALLOGENEIC or AUTOLOGOUS
Stem Cell
Transplantation
The specific questionnaire for each disease has been established by the responsible working party. Any request
for modification and improvement should be first discussed at the level of the working party which will then
transmit approved modifications to the EBMT registry sub-committee
Copyright © by EBMT, 2003
All rights reserved
Page 2
EBMT - MED B 2003 – CML - p.
1
INSTRUCTIONS FOR USE.2
G
ENERAL
I
NFORMATION
. 4
C
HRONIC
M
YELOID
L
EUKAEMIA
.. 5
F
OLLOW UP
: L
EUKAEMIAS ...
[1444]
ACUTE LYMPHOBLASTIC LEUKAEMIA NAME: STUDY NUMBER: DATE OF BIRTH ...
[9,7 KB]
From [www.lshtm.ac.uk] Last viewed: 13.07.2004
ACUTE LYMPHOBLASTIC LEUKAEMIA
NAME:
STUDY NUMBER:
DATE OF BIRTH:
NHS NUMBER:
SEX:
HOSPITAL NUMBER:
ADDRESS:
CONSULTANT:
HOSPITAL:
MARROW NUMBER:
POST CODE:
DATE OF DIAGNOSIS:
Initial Count:
Hb
FAB Classification:
MCV:
Platelets:
WBC:
<20,000
>20,000
Cytogenetics:
(please attach copy if possible)
Clinical Details (eg previous chemotherapy, splenomegaly, CNS involvement):
Immunophenotyping:
Treatment:
NEAL ? (standard)
NEAL (poor)
UKALL:
Specify:
B-ALL:
V&P:
None:
Other (specify)
Treatment started:
Initial Remission:
Transplant:
Allo:
Auto:
Date:
Relapse:
Date:
Site:
Subsequent Remission:
Date of Death:
Duration of Survival:
Comments: (eg Family ...
[1445]
The value of privacy to e-commerce, Leukaemia Foundation, 22 ...
[895,0 KB]
From [www.privacy.gov.au] Last viewed: 13.07.2004
[1446]
Structural basis for the heterodimeric interaction between the ...
[1728,6 KB]
From [www.mrc-lmb.cam.ac.uk] Last viewed: 13.07.2004
[1447]
Differential effects of oncostatin M and leukaemia inhibitory ...
[223,3 KB]
From [helios.mol.uj.edu.pl] Last viewed: 13.07.2004
Biochem. J. (2001) 355, 307–314 (Printed in Great Britain)
307
Differential effects of oncostatin M and leukaemia inhibitory factor
expression in astrocytoma cells
Aneta KASZA*, Krzysztof ROGOWSKI*, Witold KILARSKI*, Radoslaw SOBOTA*, Tytus BERNAS
†, Jurek DOBRUCKI†,
James TRAVIS
‡, Aleksander KOJ*, Marcin BUGNO* and Tomasz KORDULA*
1
*Department of Animal Biochemistry, Institute of Molecular Biology, Jagiellonian University, 31-120 Krakow, Poland,
†Department of Biophysics, Institute of Molecular
Biology, Jagiellonian University, 31-120 Krakow, Poland, and
‡Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602, U.S.A.
The effects of the production of two closely related cytokines,
oncostatin M (OSM) and leukaemia inhibitory factor (LIF), by
astrocytoma cells were investigated using the stable cell line
human U373-MG, which expressed ...
[1448]
Chronic Lymphocytic Leukaemia Trial 4
[314,6 KB]
From [www.icr.ac.uk] Last viewed: 13.07.2004
[1449]
Regulation of Tissue Factor Expression in Myeloid and Monocytic ...
[345,0 KB]
From [publications.uu.se] Last viewed: 13.07.2004
[1450]
THE PROTECTIVE EFFECT OF LEUKAEMIA INHIBITORY FACTOR (LIF) IN ...
[18,6 KB]
From [www.ans.org.au] Last viewed: 13.07.2004
leukaemia
High Voltage Lines Linked to Leukaemia
Around 100,000 homes in the UK could have potentially dangerous levels of electromagnetic radiation - such as emitted from pylons - according to latest research. The National Radiation Protection Board said one case of childhood leukaemia every two years might be associated with living near power lines. But the National Radiological Protection Board, the Government's radiation watchdog, also said 80 per cent of homes with strong electromagnetic fields are not close to pylons.
They had been working to establish whether there is a link between cancer and high-voltage overhead power lines. Their findings acknowledge an increased danger of life-threatening disease which could be blamed on living near power lines - but said they could not be sure. They estimate 100,000 homes had levels of electromagnetic fields which might contribute to two cases of childhood leukaemia each ...
[1451]
REVIEW The role of leukaemia inhibitory factor in the ...
[386,7 KB]
From [journals.endocrinology.org] Last viewed: 13.07.2004
[1452]
Structure of the mouse leukaemia inhibitory factor receptor gene ...
[980,8 KB]
From [www.biochemj.org] Last viewed: 13.07.2004
[1453]
Derivative chromosome 9 deletions in chronic myeloid leukaemia ...
[177,2 KB]
From [jcp.bmjjournals.com] Last viewed: 13.07.2004
www.verdinrete.it/ondakiller
A POOLED ANALYSIS OF MAGNETIC FIELDS AND CHILDHOOD
LEUKAEMIA
by
Anders Ahlbom1, Nick Day2, Maria Feychting1, Eve Roman3 , Jane Skinner2, John Dockerty4,
Manna Linet5, Mary McBride6 , Jorg Michaelis7 Jorgen H. Olsen8 , Tore Tynes9 & Pia K
Verkasalo10.11.12
1Division of Epidermiology, National Institute of Environmental Medicine, Karolinska Institute,
Sweden
2Strangeways Research Laboratory, University of Cambridge, United Kingdom
3Leukaemia Research Fund Centre for Clinical Epidemiology, University of Leeds, United
Kingdom
4Childhood Cancer Research Group, University of Oxford, United Kingdom
5 Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA
6Cancer Control Research Programme, British Columbia Cancer Agency, Canada
7Institute of Medical Statistics and Documentation, University of Mainz, Germany
8Institute of ...
[1454]
Synthesis and regulation of leukaemia inhibitory factor in ...
[570,1 KB]
From [molehr.oupjournals.org] Last viewed: 13.07.2004
Biochem. J. (2001) 355, 307–314 (Printed in Great Britain)
307
Differential effects of oncostatin M and leukaemia inhibitory factor
expression in astrocytoma cells
Aneta KASZA*, Krzysztof ROGOWSKI*, Witold KILARSKI*, Radoslaw SOBOTA*, Tytus BERNAS
†, Jurek DOBRUCKI†,
James TRAVIS
‡, Aleksander KOJ*, Marcin BUGNO* and Tomasz KORDULA*
1
*Department of Animal Biochemistry, Institute of Molecular Biology, Jagiellonian University, 31-120 Krakow, Poland,
†Department of Biophysics, Institute of Molecular
Biology, Jagiellonian University, 31-120 Krakow, Poland, and
‡Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602, U.S.A.
The effects of the production of two closely related cytokines,
oncostatin M (OSM) and leukaemia inhibitory factor (LIF), by
astrocytoma cells were investigated using the stable cell line
human U373-MG, which expressed ...
[1455]
Molecular detection of acute lymphoblastic leukaemia in boys with ...
[193,4 KB]
From [mp.bmjjournals.com] Last viewed: 13.07.2004
Association of early life factors and acute lymphoblastic leukaemia
in childhood: historical cohort study
L Murray*
,1
, P McCarron
1,2
, K Bailie
3
, R Middleton
1
, G Davey Smith
4
, S Dempsey
5
, A McCarthy
5
and
A Gavin
1
1
Northern Ireland Cancer Registry, Department of Epidemiology and Public Health, The Queens University, Belfast, Riddel Hall, Stranmillis Road, Belfast BT9
5EE, UK;
2
Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA;
3
Ulster Community & Hospitals Trust,
Belfast, UK;
4
Department of Social Medicine, University of Bristol, Bristol, UK;
5
Royal Group of Hospitals Trust, Belfast, UK
In a historical cohort study of all singleton live births ...
[1456]
The proline-rich region of the ecotropic Moloney murine leukaemia ...
[201,3 KB]
From [vir.sgmjournals.org] Last viewed: 13.07.2004
Association of early life factors and acute lymphoblastic leukaemia
in childhood: historical cohort study
L Murray*
,1
, P McCarron
1,2
, K Bailie
3
, R Middleton
1
, G Davey Smith
4
, S Dempsey
5
, A McCarthy
5
and
A Gavin
1
1
Northern Ireland Cancer Registry, Department of Epidemiology and Public Health, The Queens University, Belfast, Riddel Hall, Stranmillis Road, Belfast BT9
5EE, UK;
2
Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA;
3
Ulster Community & Hospitals Trust,
Belfast, UK;
4
Department of Social Medicine, University of Bristol, Bristol, UK;
5
Royal Group of Hospitals Trust, Belfast, UK
In a historical cohort study of all singleton live births ...
[1457]
Feline leukaemia provirus load during the course of experimental ...
[975,8 KB]
From [vir.sgmjournals.org] Last viewed: 13.07.2004
Association of early life factors and acute lymphoblastic leukaemia
in childhood: historical cohort study
L Murray*
,1
, P McCarron
1,2
, K Bailie
3
, R Middleton
1
, G Davey Smith
4
, S Dempsey
5
, A McCarthy
5
and
A Gavin
1
1
Northern Ireland Cancer Registry, Department of Epidemiology and Public Health, The Queens University, Belfast, Riddel Hall, Stranmillis Road, Belfast BT9
5EE, UK;
2
Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA;
3
Ulster Community & Hospitals Trust,
Belfast, UK;
4
Department of Social Medicine, University of Bristol, Bristol, UK;
5
Royal Group of Hospitals Trust, Belfast, UK
In a historical cohort study of all singleton live births ...
[1458]
Identification and phylogenetic characterization of a human T-cell ...
[910,0 KB]
From [vir.sgmjournals.org] Last viewed: 13.07.2004
Association of early life factors and acute lymphoblastic leukaemia
in childhood: historical cohort study
L Murray*
,1
, P McCarron
1,2
, K Bailie
3
, R Middleton
1
, G Davey Smith
4
, S Dempsey
5
, A McCarthy
5
and
A Gavin
1
1
Northern Ireland Cancer Registry, Department of Epidemiology and Public Health, The Queens University, Belfast, Riddel Hall, Stranmillis Road, Belfast BT9
5EE, UK;
2
Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA;
3
Ulster Community & Hospitals Trust,
Belfast, UK;
4
Department of Social Medicine, University of Bristol, Bristol, UK;
5
Royal Group of Hospitals Trust, Belfast, UK
In a historical cohort study of all singleton live births ...
[1459]
Müller-cell-derived leukaemia inhibitory factor arrests rod ...
[177,2 KB]
From [dev.biologists.org] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1460]
Hypereosinophilic Syndrome in Acute Lymphoblastic Leukaemia
[20,7 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1461]
Extramedullary presentation of acute leukaemia: a case of myeloid ...
[20,9 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1462]
Early Second Leukaemia in a Patient with Successfully Treated ...
[18,1 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1463]
Chronic Lymphocytic Leukaemia Developing in the Course of Chronic ...
[19,1 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1464]
Natural Killer Cell-triggering Receptors in Patients with Acute ...
[20,8 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1465]
Abnormal T-cell Function in B-cell Chronic Lymphocytic Leukaemia
[21,0 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1466]
The Current Status of Therapy for Adult T-cell Leukaemia ...
[20,0 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1467]
Cost analysis of the treatment of acute childhood lymphocytic ...
[19,6 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1468]
Intensified treatment of acute childhood lymphoblastic leukaemia ...
[20,2 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1469]
The prevalence of antibodies to simian T-cell leukaemia ...
[19,5 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details:
[1470]
Subcorneal Pustular Dermatosis in Association with Chronic ...
[18,7 KB]
From [taylorandfrancis.metapress.com] Last viewed: 13.07.2004
ADULT LEUKAEMIA WORKING PARTY
SERIOUS ADVERSE EVENT REPORT
Patient Identification:
Name:
.
Trial
No:
.
Centre:
.
Consultant:
.
Associated Drug:
Trial:
PT1:
Anagrelide
AML:
ATRA
Fludarabine
PSC-833
HD
AraC
(A400)
Other:
.
Adverse Event:
Definition:- A
severe adverse event is any unexpected event, which may be related
to the drug, which is (a) life threatening, or (b) requires admission to
hospital, or (c) results in significant disability, or (d) results in cancer.
SAE: .
Details: